Search

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Understanding external controls and their importance to clinical trials for rare diseases
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey
Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)